Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Q: What did Rigel (RIGL) announce on October 3, 2025 about inducement grants?

Rigel granted 41,138 options and 27,475 RSUs to 14 non-executive employees , vesting over four years with a one-year cliff.

Q: How many employees received inducement awards from Rigel (RIGL) on Oct 3, 2025?

14 non-executive employees received awards under the inducement plan.

Q: What is the vesting schedule for Rigel's (RIGL) Oct 2025 inducement grants?

Awards vest over four years with a one-year cliff .

Q: Do Rigel's (RIGL) Oct 3, 2025 inducement grants require Nasdaq rule disclosure?

Yes. Grants were made as inducements in accordance with NASDAQ Listing Rule 5635(c)(4) and disclosed by the company.

Q: What equity types did Rigel (RIGL) grant in the Oct 2025 inducement announcement?

Rigel granted stock options and restricted stock units (RSUs) .

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)

Rhea-AI Summary

Rigel Pharmaceuticals (Nasdaq: RIGL) on October 3, 2025 announced inducement equity awards under NASDAQ Listing Rule 5635(c)(4).

The company granted 41,138 stock options and 27,475 restricted stock units to 14 non-executive employees. Awards vest over four years with a one-year cliff. Grants were approved by the compensation committee under Rigel's Inducement Plan.

News Market Reaction

+1.49%

1 alert

+1.49% News Effect

On the day this news was published, RIGL gained 1.49%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

10/03/2025 - 08:05 AM

SOUTH SAN FRANCISCO, Calif., Oct. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 41,138 stock options and 27,475 restricted stock units to 14 non-executive employees vesting over four years with a one-year cliff.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.

Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com